HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lera, G. Articles by Obeso, J. A. Search for Related Content PubMed PubMed Citation Articles by Lera, G. Articles by Obeso, J. A.

Cabergoline in Parkinson's disease

Long-term follow-up

Movement Disorders Unit, Department of Neurology, Clinica Universitaria, University of Navarra, Pamplona, Spain.

We treated 36 patients with motor fluctuations and dyskinesias on chronic levodopa therapy with cabergoline (CBG) once a day for a mean period of 14.2 ± 5.8 months. There was a significant increase in the "on" hours and a reduction in "off-period" dystonia. Ten patients continued to show a marked improvement after 28.3 months of treatment (mean dose, 11.3 ± 4.5 mg). In 23 patients, increased dyskinesias (daily CBG dose, 11 ± 4.3 mg) had complicated the positive effect after 17.2 ± 4.8 months. Three patients (daily CBG dose, 14.3 mg) were therapeutic failures, and administration of CBG was stopped. Side effects leading to CBG discontinuation were visual hallucinations (n = 5), heart failure (n = 5), and nausea and vomiting (n = 1). Plasma CBG levels, measured in seven patients taking 3, 5, or 7 mg daily (po), showed fairly stable concentrations throughout the 24 hours. We concluded that CBG is an efficient dopamine agonist that can provide continuous dopaminergic stimulation when taken orally once a day.

Address correspondence and reprint requests to Dr. José A. Obeso, Neurología, Clínica Universitaria, Apartado 192, 31080, Pamplona, Navarra, Spain.

G.L. was supported by a research grant from Farmitalia-Carlo Erba (Milan, Italy.)

Presented in part at the 43rd annual meeting of the American Academy of Neurology, Boston, MA, April 1991.

Received January 12, 1993. Accepted for publication in final form April 20, 1993.

This article has been cited by other articles:

				M. P. Gillam, S. Middler, D. J. Freed, and M. E. Molitch The Novel Use of Very High Doses of Cabergoline and a Combination of Testosterone and an Aromatase Inhibitor in the Treatment of a Giant Prolactinoma J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4447 - 4451. [Abstract] [Full Text] [PDF]